Customer Letters

Please note: The following Customer Letters, do not replace the version that you receive from your local Canadian Blood Services site.

* The contents of the customer letters available on this site are current as of their dates of publication. If required, contact your local Hospital Liaison Specialist to determine if the letter is still current.

Displaying 1 - 44 of 44

	Date Sort ascending
CL_2021-44.pdf	2021-12-07	INFORMATION ONLY Blood Component and Special Request Order Form Updates Customer Letter 2021-44 (PDF) \| F040547 - Blood Component Order Form (PDF) \| 100103465 - Special Request Order Form (PDF)
CL_2021-43.pdf	2021-11-19	INFORMATION ONLY J82 Insulator Biodegradable Change Customer Letter 2021-43 (PDF) \| 1) Biodegradable EPS Letter (PDF) \| 2) Sustainable Insulation Evaluation Report (PDF) \| 4) EPS Bio Sustainable Insulation Evaluation Report (PDF) \| 5) Customer Letter 2015-24 (PDF) \| 6) Customer Letter 2015-24 - Attachment 4 Term of Use (PDF)
CL_2021-42.pdf	2021-11-01	INFORMATION ONLY Anticoagulant Labelling Changes for Apheresis Products Customer Letter 2021-42 (PDF)
CL_2021-41.pdf	2021-11-01	INFORMATION ONLY Results of the Request for Proposals (RFP) for Recombinant Plasma Protein and Related Products (PPRP) Customer Letter 2021-41 (PDF)
CL_2021-40.pdf	2021-10-29	INFORMATION ONLY Revised date for the Introduction of Pathogen-Reduced Pooled Platelets in Ottawa Ottawa site served hospitals only Customer Letter 2021-40 (PDF)
CL_2021-39.pdf	2021-10-18	ACTION REQUIRED Revised Designated PPRP Request Form and Requesting Emicizumab for Expanded Criteria Customer Letter 2021-39 (PDF) \| FAQ for Updated Designated PPRP Request Form (PDF)
CL_2021-38.pdf	2021-10-05	INFORMATION ONLY Implementation Update: Introduction of ACD-A Apheresis Frozen Plasma Customer Letter 2021-38 (PDF)
CL_2021-37.pdf	2021-09-28	INFORMATION ONLY Discontinuation of Apheresis Fresh Frozen Plasma 500mL Customer Letter 2021-37 (PDF)
CL_2021-36.pdf	2021-09-22	INFORMATION ONLY Introduction of Additional Component Bags Customer Letter 2021-36 (PDF)
CL_2021-35.pdf	2021-09-10	INFORMATION and ACTION REQUIRED Blood and Blood Product Deliveries: Potential Impact of Hospital Mandatory Vaccination Policies Customer Letter 2021-35 (PDF)
CL_2021-34.pdf	2021-09-08	INFORMATION ONLY Emicizumab (Hemlibra®) for severe hemophilia A without FVIII inhibitors Customer Letter 2021-34 (PDF)
CL_2021-33.pdf	2021-09-01	INFORMATION FOR ALBERTA HOSPITAL CUSTOMERS ONLY Transfer of Red Cell (HEA and RHCE) Genotype Testing Customer Letter 2021-33 (PDF)
CL_2021-32.pdf	2021-07-26	INFORMATION ONLY ADYNOVATE® Updates Customer Letter 2021-32 (PDF) \| ADYNOVATE Customer Letter (PDF)
CL_2021-31.pdf	2021-06-29	INFORMATION ONLY Introducing Pathogen-Reduced Pooled Platelets in Ottawa Customer Letter 2021-31 (PDF)
CL_2021-30.pdf	2021-06-28	INFORMATION ONLY Revision of Request for Serological Investigation Form Customer Letter 2021-30 (PDF) \| Request for Serological Investigation (PDF)
CL_2021-29.pdf	2021-06-09	INFORMATION ONLY Fibrinogen concentrate – no restrictions on brand mix Customer Letter 2021-29 (PDF)
CL_2021-28.pdf	2021-05-21	ACTION REQUIRED Introducing pathogen-reduced Pooled Platelets and associated new ISBT Component Codes Ottawa site served hospitals only Customer Letter 2021-28 (PDF)
CL_2021-27.pdf	2021-05-13	ACTION REQUIRED Recall Notification Distribution Customer Letter 2021-27 (PDF) \| NCRW Example (JPG)
CL_2021-26.pdf	2021-05-10	ACTION REQUIRED Introduction of ACD-A Apheresis Frozen Plasma Customer Letter 2021-26 (PDF)
CL_2021-25.pdf	2021-05-03	INFORMATION ONLY Hizentra® 20% Liquid 20 mL (4g) Pre-filled Syringe Availability Customer Letter 2021-25 (PDF) \| Hizentra® Prefilled Syringe (PDF) \| Hizentra® Fact Sheet (PDF)
CL_2021-24.pdf	2021-04-28	INFORMATION ONLY Special Request Order Form Customer Letter 2021-24 (PDF)
CL_2021-23.pdf	2021-04-22	INFORMATION ONLY Albumin 5% 500 mL Availability Customer Letter 2021-23 (PDF) \| Albumin 5% Introduction Letter (PDF) \| Product Profile Albumin (PDF)
CL_2021-22.pdf	2021-04-19	INFORMATION ONLY Bacterial Test Result Notification to Hospitals – New Form Customer Letter 2021-22 (PDF) \| Bacterial Testing Results Notification (PDF)
CL_2021-21.pdf	2021-04-08	INFORMATION ONLY Introduction of Fibryga® Kit - Now Co-Packaged with Water for Injection Customer Letter 2021-21 (PDF) \| Fibryga Kit with WFI CBS HCP Customer Letter (PDF)
CL_2021-20.pdf	2021-03-18	INFORMATION ONLY Updated Share Splits for Intravenous Immunoglobulins Customer Letter 2021-20 (PDF)
CL_2021-19.pdf	2021-03-15	INFORMATION ONLY RiaSTAP^® Reconstitution Devices “Spike and Syringe Filter” available in RiaSTAP® package Customer Letter 2021-19 (PDF) \| RiaSTAP® Reconstitution Devices “Spike and Syringe Filter” now available in RiaSTAP^® package (PDF)
CL_2021-18.pdf	2021-03-15	INFORMATION ONLY Introduction of HAEGARDA® Customer Letter 2021-18 (PDF) \| Product Profile Template HAEGARDA® (PDF) \| HAEGARDA vendor letter (PDF)
CL_2021-17.pdf	2021-03-03	INFORMATION ONLY Intravenous Immunoglobulin (IVIg) Brand Switching Guidance and Resources from The National Advisory Committee on Blood and Blood Products (NAC) Customer Letter 2021-17 (PDF) \| Intravenous Immunoglobulin (IVIg) Brand Switching (PDF)
CL_2021-16.pdf	2021-02-23	INFORMATION ONLY Follow-up of Canadian Blood Services Platelet Bacterial Testing Results Customer Letter 2021-16 (PDF) \| Follow-up of Canadian Blood Services Platelet Bacterial Testing Results (PDF)
CL_2021-15.pdf	2021-02-18	INFORMATION ONLY Updates regarding Hemlibra^® (emicizumab injection) Customer Letter 2021-15 (PDF) \| Drug Product Shelf Life Reduction (PDF) \| Introduction of Transfer Needle with Filter (PDF)
CL_2021-14.pdf	2021-02-17	INFORMATION ONLY Octagam^® 10% Availability Customer Letter 2021-14 (PDF) \| Product Profile Octagam (PDF) \| Octagam Availability Customer Letter (PDF)
CL_2021-13.pdf	2021-02-16	INFORMATION ONLY New CSL Behring Contact Number for Urgent Inquiries and Afterhours Service Customer Letter 2021-13 (PDF) \| CSL Behring Contact Number (PDF)
CL 2021-12.pdf	2021-02-12	INFORMATION ONLY WinRho® SDF Labelling – Repackaged WinRho® SDF 1000 mcg (5000 IU) Lot 230029571 Customer Letter 2021-12 (PDF) \| Customer notification repackaging activity for WinRho® (PDF)
CL_2021-11.pdf	2021-02-11	INFORMATION ONLY Updates to Solvent Detergent Plasma - Request Form Customer Letter 2021-11 (PDF) \| Solvent Detergent Plasma - Request Form
CL 2021-10.pdf	2021-02-08	ACTION REQUIRED Hospital Monitoring of Ig Supply Customer Letter 2021-10 (PDF)
CL 2021-09.pdf	2021-02-08	INFORMATION ONLY Introduction of X-ray Irradiation Customer Letter 2021-09 (PDF)
CL_2021-08.pdf	2021-02-05	ACTION REQUIRED Immunoglobulin (Ig) Inventory Update and Reminder of Action for Hospitals Customer Letter 2021-08 (PDF) \| National Emergency Blood Management Committee Letter (PDF)
CL_2021-07.pdf	2021-02-03	INFORMATION ONLY Updates to the Blood Component and Special Request Order Forms Customer Letter 2021-07 (PDF) \| Blood Component Order Form (PDF) \| Special Request Order Form (PDF)
CL_2021-06.pdf	2021-02-02	INFORMATION ONLY Update to J82 and E38 Shipping Containers for Inter-Hospital Transfers Customer Letter 2021-06 (PDF)
CL_2021-05.pdf	2021-01-25	INFORMATION ONLY Release of Revised Circular of Information for Red Blood Cells, Platelets, and Plasma Customer Letter 2021-05 (PDF)
CL_2021-04.pdf	2021-01-22	INFORMATION ONLY WinRho® SDF Labelling Customer Letter 2021-04 (PDF) \| Saol Customer Notification
CL_2021-03.pdf	2021-01-21	INFORMATION ONLY Privigen® Inventory Customer Letter 2021-03 (PDF)
CL_2021-02.pdf	2021-01-18	INFORMATION ONLY Update on Panhematin® Packing Supply Customer Letter 2021-02 (PDF)
CL_2021-01.pdf	2021-01-11	INFORMATION ONLY Revision to Transfusion Related Acute Lung Injury (TRALI) Patient Data Form Customer Letter 2021-01 (PDF)